At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 46 enrolled
Drug / intervention
GM-1020drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Two-Part Controlled Clinical Study to Evaluate Safety, Tolerability, Response, Pharmacokinetics and Pharmacodynamics of Single and Multiple Oral Doses of GM-1020 in Patients With Major Depressive Disorder
In Brief
A Phase 2 clinical trial evaluating GM-1020 for Major Depressive Disorder. Completed, enrolled 46 participants across 1 site.
Detailed Summary
The aim of this Phase 2a study in patients with MDD is to assess safety and tolerability and preliminary antidepressant efficacy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
202420252026
Enrollment StartFeb 2024
First PostedMar 2024
Primary CompletionMar 2025
Study CompletionMar 2025
TodayJul 2026
First PostedMar 13, 2024
Enrollment StartFeb 1, 2024
Primary CompletionMar 4, 2025
Study CompletionMar 27, 2025
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 2.3 years ago
Interventions
GM-1020drug
N-methyl-D-aspartate (NMDA) receptor antagonist